Sunosi(solriamfetol)
Sunosi (solriamfetol) is a small molecule pharmaceutical. Solriamfetol was first approved as Sunosi on 2019-06-17. It is used to treat sleepiness in the USA. It has been approved in Europe to treat narcolepsy and obstructive sleep apnea. It is known to target sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Trade Name
FDA
EMA
Sunosi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Solriamfetol hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SUNOSI | Axsome Malta | N-211230 RX | 2019-06-17 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
sunosi | New Drug Application | 2022-06-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
sleepiness | — | D000077260 | R40.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
SOLRIAMFETOL HYDROCHLORIDE, SUNOSI, AXSOME MALTA | |||
2026-06-17 | ODE-254 | ||
2024-06-17 | NCE |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Solriamfetol Hydrochloride, Sunosi, Axsome Malta | |||
10940133 | 2040-03-19 | U-3099 | |
11160779 | 2040-03-19 | U-3521 | |
11560354 | 2039-03-06 | DP | U-3520 |
10912754 | 2038-06-01 | U-3082 | |
10959976 | 2038-06-01 | U-3151 | |
11648232 | 2038-06-01 | U-3602 | |
10195151 | 2037-09-05 | DP | |
10512609 | 2037-09-05 | U-2548 | |
11439597 | 2037-09-05 | DP | |
8440715 | 2027-08-25 | U-2548 | |
8877806 | 2026-06-07 | U-2548 | |
9604917 | 2026-06-07 | U-2548 | |
10351517 | 2026-06-07 | U-2548 |
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | 3 | 2 | — | 6 |
Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 3 | 2 | 1 | — | 6 |
Sleepiness | D000077260 | R40.0 | — | 3 | — | 2 | — | 5 | |
Circadian rhythm sleep disorders | D020178 | G47.2 | — | — | — | 1 | — | 1 | |
Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | 1 | — | 1 |
Binge-eating disorder | D056912 | F50.2 | — | — | — | 1 | — | 1 | |
Postpartum period | D049590 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | SOLRIAMFETOL |
INN | solriamfetol |
Description | Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. It is taken by mouth.
|
Classification | Small molecule |
Drug class | Norepinephrine–dopamine reuptake inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)OC[C@H](N)Cc1ccccc1 |
Identifiers
PDB | — |
CAS-ID | 178429-62-4 |
RxCUI | 2121751 |
ChEMBL ID | CHEMBL4297620 |
ChEBI ID | — |
PubChem CID | 10130337 |
DrugBank | DB14754 |
UNII ID | 939U7C91AI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC6A3
SLC6A3
SLC6A2
SLC6A2
Organism
Homo sapiens
Gene name
SLC6A3
Gene synonyms
DAT1
NCBI Gene ID
Protein name
sodium-dependent dopamine transporter
Protein synonyms
DA transporter, dopamine transporter 1, solute carrier family 6 (neurotransmitter transporter), member 3, solute carrier family 6 (neurotransmitter transporter, dopamine), member 3, Solute carrier family 6 member 3
Uniprot ID
Mouse ortholog
Slc6a3 (13162)
sodium-dependent dopamine transporter (Q9R1I2)
Variants
Clinical Variant
No data
Financial
Sunosi - Jazz Pharmaceuticals
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 281 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
55,986 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more